Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Randomized, Placebo and Ciclosporin Controlled Study of ISA247 in Plaque Psoriasis Patients (ESSENCE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00408187
Recruitment Status : Completed
First Posted : December 6, 2006
Last Update Posted : July 30, 2009
Information provided by:
Aurinia Pharmaceuticals Inc.

Brief Summary:
The purpose of this study is to determine the safety and efficacy of voclosporin in patients with plaque psoriasis.

Condition or disease Intervention/treatment Phase
Psoriasis Drug: voclosporin Drug: Ciclosporin Drug: Placebo Phase 3

Detailed Description:
Psoriasis is a chronic skin condition that can have a significant impact on a patient's physical and mental well being. The most common form of psoriasis is plaque psoriasis. Targeted treatments in psoriasis have been reported recently, yet ciclosporin, a calcineurin inhibitor (CNi) remains one of the treatments which has the greatest efficacy. Voclosporin represents the possibility of a calcineurin inhibitor which is not only as efficacious as ciclosporin A, but also has an improved toxicity profile.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 642 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III, Randomized, Multicentre, Double-Blind, Placebo and Ciclosporin Controlled Study of ISA247 in Plaque Psoriasis Patients
Study Start Date : December 2006
Actual Primary Completion Date : December 2008
Actual Study Completion Date : December 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis

Arm Intervention/treatment
Active Comparator: 1. Drug: voclosporin
voclosporin 0.4 mg/kg po BID

Placebo Comparator: 3. Drug: Placebo

Active Comparator: 2. Drug: Ciclosporin
ciclosporin 1.5 mg/kg po BID

Primary Outcome Measures :
  1. Superiority in the proportion of subjects achieving a score of "clear" or "almost clear" in the Static Physician's Global Assessment (SPGA) score [ Time Frame: Twelve weeks of treatment ]

Secondary Outcome Measures :
  1. To show non-inferiority of voclosporin compared to ciclosporin in the proportion of subjects achieving a score of "clear" or "almost clear" in the Static Physician's Global Assessment (SPGA) score at [ Time Frame: Twelve weeks of treatment ]
  2. Superiority in de novo hypertriglyceridemia, defined as proportion of patients developing fasting triglycerides greater than or equal to 1.7 mmol/L [ Time Frame: Twenty four weeks of treatment ]
  3. Superiority in de novo hypertension, defined as proportion of patients developing blood pressure greater than or equal to 140 mmHg (systolic) or greater than or equal to 90 mmHg (diastolic) [ Time Frame: Twenty four weeks of treatment ]
  4. Superiority of renal function, defined as the proportion of patients experiencing a confirmed greater than or equal to 30% rise in serum creatinine [ Time Frame: Twenty four weeks of treatment ]
  5. Superiority in proportion of patients achieving a 75% reduction in the Psoriasis Area and Severity Index (PASI) score (PASI-75) [ Time Frame: Twelve weeks of treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Aged greater than or equal to 18 years of age inclusive at time of screening.
  • Diagnosed with plaque psoriasis greater than or equal to 6 months prior to screening.
  • Diagnosis of stable, plaque psoriasis; i.e. psoriasis must not be spontaneously improving or worsening in the 4 weeks prior to the screening visit.
  • Psoriasis failing at least one systemic treatment regimen or where other systemic therapies are contraindicated or where tolerability is an issue.
  • Plaque psoriasis involving greater than or equal to 10% of the body surface area and a SPGA score greater than or equal to 3 at screening and prior to randomization at the day 0 visit.
  • Not pregnant or nursing.
  • Sexually active women of childbearing potential or less than 1 year post-menopausal and sexually active men who are not surgically sterile must use a reliable form of birth control during study treatment and for at least 3 months after the last dose of study drug. Surgically sterile females are not considered to be of childbearing potential. Reliable forms of birth control include oral or depot contraceptives, and double-barrier methods.
  • Written informed consent prior to washout and screening procedures.
  • Able to keep study appointments and cooperate with all study requirements, in the opinion of the Investigator.

Exclusion Criteria:

  • Has generalized erythrodermic, guttate, or pustular psoriasis.
  • Have other dermatoses that would interfere with the evaluation of psoriasis, at the discretion of the Investigator.
  • A current malignancy or history of malignancy within 5 years or a history of lymphoma at any time. Subjects can be enrolled with a history of squamous or basal cell carcinoma that has been surgically excised or removed with curettage and electrodesiccation.
  • Has a current, uncontrolled bacterial, viral, or fungal infection that requires intravenous antibiotics or antifungals or has had such infections within 60 days prior to screening.
  • A known history of tuberculosis.
  • Serologic evidence or known latent HIV, HBV or HCV virus.
  • Uncontrolled hypertension of systolic blood pressure greater than or equal to 160 mmHg or diastolic blood pressure greater than or equal to 90 mmHg.
  • MDRD GFR < 60 mL/min.
  • Variation between the screening and Visit 1 SCr greater than or equal to 30%.
  • ALT, AST, GGT greater than or equal to 2x upper limit of normal (ULN).
  • White blood cell count less than or equal to 2.8 x 10 to the ninth power/L.
  • Requires the following prohibited medications or treatments during the washout or treatment period: drugs potentiating the nephrotoxicity of voclosporin, drugs interfering with its pharmacokinetics, drugs considered to contribute to psoriasis flare; or, systemic and topical psoriasis medication that may interfere with assessment of study drug efficacy.
  • Has used any investigational drug or device within 30 days or 10 half lives (whichever is longer) prior to the screening visit.
  • Current participation in another clinical trial of any drug or biological agent.
  • Has taken biological agent(s), except flu shots, tetanus shots, or boosters, within 3 months of randomization. Biological agents include any virus, live vaccine, therapeutic serum, toxin, antitoxin, monoclonal antibodies or analogous product applicable to the prevention, treatment, or cure of diseases or injuries of man.
  • Previous exposure to voclosporin.
  • A history of clinically defined allergy to ciclosporin, constituents of Neoral or any of the constituents of the ISA247 formulation.
  • A history of alcoholism or drug addiction.
  • Weighs < 45kg (99 lbs).
  • A history of disease, including mental/emotional disorder that would interfere with the subject's participation in the study, in the evaluation of his/her response or that might cause the administration of voclosporin to pose a significant risk to the subject, in the opinion of the Investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00408187

Show Show 49 study locations
Sponsors and Collaborators
Aurinia Pharmaceuticals Inc.
Layout table for investigator information
Principal Investigator: Wayne Gulliver, M.D. NewLab Clinical Research
Principal Investigator: Vincent Ho, M.D. UBC
Principal Investigator: Andrzej Langner, Prof. Dr. IWOLANG
Principal Investigator: Thomas A. Luger, Prof. Dr. University of Muenster
Principal Investigator: Slawomir Majewski, Prof. Dr. Akademia Medyczna
Principal Investigator: Wolfram Sterry, Prof. Dr. Charite Universitatsmedizin Berlin

Layout table for additonal information
Responsible Party: Robert Huizinga, Isotechnika Identifier: NCT00408187    
Other Study ID Numbers: ISA05-25
First Posted: December 6, 2006    Key Record Dates
Last Update Posted: July 30, 2009
Last Verified: July 2009
Keywords provided by Aurinia Pharmaceuticals Inc.:
Randomized Controlled Trials
Chronic Disease
Dermatologic Agents
Middle Aged
Severity of Illness Index
Treatment Outcome
Quality of Life
Double-Blind Method
Additional relevant MeSH terms:
Layout table for MeSH terms
Skin Diseases, Papulosquamous
Skin Diseases
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antifungal Agents
Anti-Infective Agents
Dermatologic Agents
Antirheumatic Agents
Calcineurin Inhibitors